The populations of two Western Desert Egyptian oases have been studied for various genetic markers of the blood and some anthropological characters. Hb AS was found in 9%. Blood group frequencies were similar in both oases; 10.2% were RhD-negative, G-6-PD deficiency was found in 7.5 %; GdA had a frequency of 1 % in El-Kharga and 16% in El-Dakhla; PGDC was 5.5% in El-Kharga and 6.2 % in El-Dakhla. All individuals examined were homozygous for AK1; acid phosphatase gene frequencies in El-Kharga were Pa = 0.1475, Pc = 0.0164, Pr= 0.0164; in El-Dakhla, Pa = 0.0667, Pc = 0.00, Pr = 0.0333; in El-Kharga the Hp gene had a frequency of 0.4415, Hpo-o = 8.29%; in El-Dakhla, Hp1 had a frequency of 0.3245, Hpo-o = 3.39%. The information provided points to a mixture of Caucasian and negroid features in the populations studied. The negroid influence is more marked in the El-Dakhla oasis. Head measurements show that El-Kharga males reveal more Caucasoid stock and are closer to the Upper Egyptians than most populations of the neighboring oases.

Keywords:
Egyptian oases, Hemoglobin variants, Blood, serum and enzyme groups, Anthropometry
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.